Cargando…

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis

BACKGROUND: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. AIMS: The current study assessed the effectiveness of itolizumab in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parthasaradhi, Anchala, Singh, Vinay, Parasramani, S. G., Yadav, Nishi, Krupashankar, D. S., Soni, Manish, Bansal, Rakesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518574/ https://www.ncbi.nlm.nih.gov/pubmed/28761839 http://dx.doi.org/10.4103/idoj.IDOJ_330_16

Ejemplares similares

Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla, Leelavathy, et al.
Publicado: (2019)

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
por: Singh, Vinay
Publicado: (2016)

Psoriasis Management During the COVID-19 Pandemic: Recommendations by SIG Psoriasis (IADVL Academy)
por: Ganguly, Satyaki, et al.
Publicado: (2021)

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017)

Congenital atrichia associated with nevus flammeus: A rare association
por: Kirit, EP Raj, et al.
Publicado: (2014)

Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]
Publicado: (2015)

Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
por: Menon, Roshni, et al.
Publicado: (2015)

Severe bronchospasm following itolizumab infusion in a COVID-19 patient
por: Kumar, Neeraj, et al.
Publicado: (2022)

Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience
por: De, Abhishek, et al.
Publicado: (2020)

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
por: Graier, T., et al.
Publicado: (2022)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
por: Becher, Gabrielle, et al.
Publicado: (2022)

Prevalence and relevance of secondary contact sensitizers in subjects with psoriasis
por: Krupashankar, D. S., et al.
Publicado: (2012)

Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
por: Atal, Shubham, et al.
Publicado: (2020)

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab
por: Caballero, Armando, et al.
Publicado: (2020)

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
por: MÄLKÖNEN, Tarja, et al.
Publicado: (2022)

Inflammasome Related Mediators and Their Association with Disease Determinants in Chronic Plaque Psoriasis
por: Chhabra, Seema, et al.
Publicado: (2021)

Ustekinumab in the therapy of chronic plaque psoriasis
por: O’Neill, Jenna L, et al.
Publicado: (2009)

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Adverse drug reactions of itolizumab in COVID-19 patient: A case report
por: Mohammed, Ziauddin, et al.
Publicado: (2022)

Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan
por: Chen, Yu-Chen, et al.
Publicado: (2020)

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
por: Gambardella, Alessio, et al.
Publicado: (2021)

Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus
por: Burlando, Martina, et al.
Publicado: (2022)

The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice
por: Choi, Chong Won, et al.
Publicado: (2017)

Prolidase activity in chronic plaque psoriasis patients
por: Sürücü, Hacer Altın, et al.
Publicado: (2015)

Chronic erythema nodosum with koebnerization to plaque psoriasis()()
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Development of Dermatitis Herpetiformis in Chronic Plaque Psoriasis
por: Lee, Ruby, et al.
Publicado: (2021)

Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
por: Armstrong, April W., et al.
Publicado: (2022)

Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program “Treatment of moderate and severe forms of plaque psoriasis (B.47)” of the National Health Fund in Poland
por: Owczarek, Witold, et al.
Publicado: (2021)

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2017)

Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19
por: Kumar, Abhyuday, et al.
Publicado: (2021)

Real-world treatment patterns, patient-reported outcomes, and effectiveness of flexibledosing etanercept in patients with plaque psoriasis in Greece
por: Rigopoulos, Dimitris, et al.
Publicado: (2022)

The Cost Effectiveness of Biologic Therapy for the Treatment of Chronic Plaque Psoriasis in Real Practice Settings in Italy
por: Spandonaro, Federico, et al.
Publicado: (2014)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

Guselkumab for plaque psoriasis
Publicado: (2019)

Bimekizumab for plaque psoriasis
Publicado: (2022)

The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
por: Jenneck, Claudia, et al.
Publicado: (2007)

Potential role of ustekinumab in the treatment of chronic plaque psoriasis
por: Mercuri, Santo Raffaele, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cfsi9vn5g2fg9gaea0l3v7eick